Medplus Subsidiary Faces Multiple Drug License Suspensions Across Karnataka and Telangana
Medplus Health Services Limited confirmed that its subsidiary, Optival Health Solutions Private Limited, has received three separate suspension orders for Drug Licenses pertaining to stores in the states of Telangana and Karnataka. The suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.The orders were received on May 27, 2026, from various Drugs Control Administrations. The suspensions involve three different locations and result in a potential total revenue loss.
The details of the suspensions, the affected locations, and the quantifiable financial impact are outlined below:
| Authority | Location | Suspension Period | Potential Revenue Loss |
|---|---|---|---|
| Assistant Director, Drugs Control Administration, Shameerpet-Mechel-Malkajgiri Dist, Telangana | Maruthi Nagar Kothapet Village, Telangana | Three days | Rs 1.35 lacs |
| Assistant Director, Drugs Control Administration Bangalore Rural Circle, Devanahalli, Karnataka | Channappa Layout Nelamangala, Karnataka | Two days | Rs 1.49 lacs |
| Assistant Director, Drugs Control Administration Bangalore circle-5, Bangalore, Karnataka | Binny Mill Road Ganganagar, Karnataka | One day | Rs 0.65 lacs |
The suspensions impact the company's operational activity in the listed states. The potential financial impact due to the three suspensions amounts to a combined revenue loss.
MEDPLUS Stock Price Movement
On Wednesday, Medplus Health Services Limited shares edged higher, gaining 0.10% and closing at ₹883.3. The equity found support throughout the session, trading on a volume of 143,886 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.